Abstract
Milacemide (2-n-pentylaminoacetamide) hydrochloride was administered by continuous i.v. infusion for up to 7 days, at 300 and 600 mg/kg per day to male Sprague-Dawley rats. This was intended to provide high and sustained exposure to evaluate the effect of a preterminal 24-h fast on liver lipid content. Liver lipid content, as assessed by triglyceride concentration and histopathology, was not different in saline controls or rats infused with up to 600 mg/kg per day for up to 7 days, when they had access to food up to sacrifice. When the rats were fasted for 24 h before sacrifice, milacemide produced microsteatosis in the periportal and midzonal areas. The effect was significant after 2 days of infusion at 600 mg/kg per day and increased in intensity with duration of administration. After 7 days of infusion, at 600 mg/kg per day, liver triglycerides increased by more than 4-fold in rats fasted for the last 24 h. No other differences from the controls were observed at light microscopy or in liver protein content and AST activity. Liver ALT activity was decreased by 28% and plasma ALT activity by 23%. Plasma triglyceride levels were lowered by milacemide, in both fasted and fed rats. This study demonstrates that fasting for 24 h triggers the development of liver microsteatosis in rats exposed to milacemide. Fasting has been previously described to increase liver microsteatosis after administration of sodium valproate, 4-en valproate and pentenoic acid in the rat. These findings might help to identify the mechanism of the hepatic effects of milacemide. Such effects were not observed in the regular animal toxicity studies conducted by the oral route. Some patients, however, presented evidence of liver dysfunction.
Similar content being viewed by others
References
Carleer J, Debruyne E, Cavalier R, Hérin M, Burton E, Roba J (1992) Effects of milacemide on the liver in the cynomolgus monkey. Toxicol Lett Suppl: 243–244
Christophe J, Kutzner R, Nguyen-Bui WD, Damien C, Chatelain P, Gillet C (1983) Conversion of orally administered 2-n-pentylaminoacetamide into glycinamide and glycine in the rat brain. Life Sci 33: 533–541
Dysken MW, Mendels J, LeWitt P, Reisberg B, Pomara N, Wood J, Fakouhi TD, Herting R (1992a) Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type. J Am Geriatr Soc 40: 503–506
Dysken MW, Fakouhi TD, Skare SS, Mendels J, LeWitt P, Hendrie HC, Venable TC, Hantsbarger GL, Herting R (1992b) Milacemide: safety assessment in senile dementia of the Alzheimer type. Drug Dev Res 27: 67–72
Eadie MJ, Hooper WD, Dickinson RG (1988) Valproate-associated hepatotoxicity and its biochemical mechanisms. Med Toxicol 3: 85–106
Granneman GR, Wang SI, Kesterson JW, Machinist JM (1984) The hepatotoxicity of valproic acid and its metabolites in rats. II. Intermediary and valproic acid metabolism. Hepatology 4: 1153–1158
Handelmann GE, Nevins ME, Mueller LL, Arnolde SM, Cordi AA (1989) Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic rodents. Pharmacol Biochem Behav 34: 823–828
Höhn VH, Gartzke J, Burk D (1987) Methode zur enzymatischen Bestimmung der Triglyceride im Leberhomogenat. J Clin Chem Clin Biochem 25: 743–745
Hong J, Pan J, Gonzalez FJ, Gelboin HV, Yang CS (1987) The induction of a specific form of cytochrome P-450 (P-450j) by fasting. Biochem Biophys Res Commun 142: 1077–1083
Houtkooper MA, Van Oorschot CAEH, Rentmeester TW, Hoppener PJEA, Onkelinx C (1986) Double-blind study of milacemide in hospitalized therapy-resistant patients with epilepsy. Epilepsia 27: 255–262
Janssens de Varebeke Ph, Pauwels G, Buyse C, David-Remacle M, De Mey J, Roba J, Youdim MBH (1989) The novel neuropsychotropic agent milacemide is a specific enzyme-activated inhibitor of brain monoamine oxidase B. J Neurochem 53: 1109–1116
Janssens de Varebeke Ph, Schallauer E, Rausch WD, Riederer P, Youdim MBH (1990) Milacemide, the selective substrate and enzyme-activated specific inhibitor of monoamine oxidase B, increases dopamine but not serotonin in caudate nucleus of Rhesus monkey. Neurochem Int 17: 325–329
Kesterson JW, Granneman GR, Machinist JM (1984) The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 4: 1143–1152
Lane AE, Mavriedes C (1969) Automation of the biuret method for samples of low protein concentrations. Anal Biochem 27: 363–366
Lipkin EW, Cooper C, Shipley RA (1978) The contribution of serum triacylglycerol to hepatic triacylglycerol turnover in the starved rat. Biochem J 172: 205–218
Ndangiza A, Masson M, Palate B, Roba J (1992a) Effect of fasting on the liver toxicity of a single oral dose of sodium valproate, 4-en valproic acid, pentenoic acid, pentanoic acid and 2-n-pentylaminoacetamide in the rat. Toxicol Lett Suppl: 326
Ndangiza A, Catillon H, van Dorsser W, Roba J (1992 b) Acute toxicity studies of 2-n-pentylaminoacetamide hydrochloride. J Am Coll Toxicol 11: 716
Norton LC, Laxer KD, Schomer D, Osborn P (1986) Phase II study to evaluate the efficacy and safety of milacemide (CP1552S) in the treatment of complex partial seizures in adult patients. Epilepsia 27: 648
Porubek DJ, Grillo MP, Baillie TA (1989) The covalent binding to protein of valproic acid and its hepatotoxic metabolite, 2-n-propyl-4-pentenoic acid, in rats and in isolated rat hepatocytes. Drug Metab Dispos 17: 123–130
Price VF, Miller MG, Jollow DJ (1987) Mechanisms of fasting-induced potentiation of acetaminophen hepatotoxicity in the rat. Biochem Pharmacol 36: 427–433
Rettie AE, Rettenmeier AW, Howald WN, Baillie TA (1987) Cytochrome P-450-catalyzed formation of Δ4-VPA, a toxic metabolite of valproic acid. Science 235: 890–893
Roba J, Cavalier R, Cordi A, Gorissen H, Hérin M, Janssens de Varebeke Ph, Onkelinx C, Remacle H, van Dorsser W (1986) Milacemide. In: Meldrum BS, Porter RJ (eds). New anticonvulsant drugs. Libbey, London Paris, pp 179–190
Rogiers V, Vandenberghe Y, Geerts A, Callaerts A, Carleer J, Vercruysse A, Roba J (1992) Effects of milacemide in vivo on xenobiotic biotransformation and lipid metabolism, studied with isolated rat hepatocytes. Toxicol Lett Suppl: 244
Rothacker DL, Kanerva RL, Wyder WE, Alden CL, Maurer JK (1988) Effects of variation of necropsy time and fasting on liver weights and liver components in rats. Toxicol Pathol 16: 22–26
Schotz MC, Baker N, Chavez MN (1964) Effect of carbon tetrachloride ingestion on liver and plasma triglyceride turnover rates. J Lipid Res 5: 569–577
Semba J, Patsalos PN (1993) Milacemide effects on the temporal interrelationship of amino acids and monoamine metabolites in rat cerebrospinal fluid. Eur J Pharmacol 230: 321–326
Semba J, Curzon G, Patsalos PN (1993) Antiepileptic drug phamacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide. Br J Pharmacol 108: 1117–1124
Shimizu M, Morita S (1992) Effects of feeding and fasting on hepatolobular distribution of glutathione and cadmium-induced hepatotoxicity. Toxicology 75: 97–107
Thayer WS (1984) Inhibition of mitochondrial fatty acid oxidation in pentenoic acid-induced fatty liver. A possible model for Reyes syndrome. Biochem Pharmacol 33: 1187–1194
van Dorsser W, Barris D, Cordi A, Roba J (1983) Anticonvulsant activity of milacemide. Arch Int Pharmacodyn 266: 239–249
Waltregny A, Onkelinx C (1983) Initial results with milacemide in epileptic patients. Neurol Psychiatry 6: 158–173
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rakotoamboa, JL., Masson, M., Palate, B. et al. Fasting for 24 h reveals liver microsteatosis after continuous i.v. infusion of milacemide in the rat. Arch Toxicol 68, 266–271 (1994). https://doi.org/10.1007/s002040050067
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s002040050067